Heart-Drug Study Reverts to Original Path
December 17, 2007
Two pharmaceutical companies reversed plans to change direction in a heart-drug study of Vytorin and they’re back to the original course.
Officials last month said they planned to change the statistical analysis of a jointly sponsored study of Vytorin, a drug that combines two anti-high-cholesterol drugs — Merck & Co.’s Zocor and Schering-Plough’s Zetia, the Wall Street Journal reported. The study aims to determine if the drugs combined make the now-off-patent Zocor more effective.
If Zocor is more effective in combination, insurers would be more inclined to approve $3-a-day Vytorin than cheaper, generic forms of Zocor, the Journal said.
Study results are expected in March.